1. Home
  2. YJ vs ERNA Comparison

YJ vs ERNA Comparison

Compare YJ & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunji Inc. American Depository Shares

YJ

Yunji Inc. American Depository Shares

HOLD

Current Price

$1.25

Market Cap

9.1M

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

HOLD

Current Price

$3.92

Market Cap

7.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YJ
ERNA
Founded
2015
2018
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.8M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
YJ
ERNA
Price
$1.25
$3.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.2K
574.8K
Earning Date
03-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$0.13
52 Week High
$2.67
$15.88

Technical Indicators

Market Signals
Indicator
YJ
ERNA
Relative Strength Index (RSI) 39.91 34.26
Support Level $1.26 $0.23
Resistance Level $1.62 $7.94
Average True Range (ATR) 0.08 0.82
MACD -0.00 -0.22
Stochastic Oscillator 3.54 3.54

Price Performance

Historical Comparison
YJ
ERNA

About YJ Yunji Inc. American Depository Shares

Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: